Peptide-drug Conjugate Information
General Information of This Peptide-drug Conjugate (PDC)
| PDC ID |
PDC_00236
|
|||||
|---|---|---|---|---|---|---|
| PDC Name |
M1-PTX
|
|||||
| PDC Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Glioma
|
|||||
| Structure |
|
|||||
| Peptide Name |
M1
|
Peptide Info | ||||
| Drug Name |
Paclitaxel
|
Drug Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Succinic Acid
|
Linker Info | ||||
| Formula |
C194H252N34O54
|
|||||
| #Ro5 Violations (Lipinski): 4 | Molecular Weight | 3924.334 | ||||
| Lipid-water partition coefficient (xlogp) | -1.9678 | |||||
| Hydrogen Bond Donor Count (hbonddonor) | 36 | |||||
| Hydrogen Bond Acceptor Count (hbondacc) | 57 | |||||
| Rotatable Bond Count (rotbonds) | 99 | |||||
Full List of Activity Data of This Peptide-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Glioma | ||||
| Efficacy Data | Percent survival |
0%
|
|||
| Administration Time | 25 days | ||||
| Administration Dosage | Normalized to 17.3 mg/kg PTX | ||||
| Description |
The survival of the PTX group was markedly lower than that of the Vehicle group. M1-PTX did not improve survival, whereas the survival of the M1-RGD-PTX group was increased.
|
||||
| In Vivo Model | U87MG-Luc-bearing xenograft model. | ||||
| In Vitro Model | Glioblastoma | U87MG-Luc cell | CVCL_5J15 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Glioma | ||||
| Efficacy Data | Cell viability |
60%
|
|||
| Administration Time | 24 h | ||||
| Administration Dosage | 100 nM | ||||
| Evaluation Method | MTS assay | ||||
| Description |
Both PDCs showed higher in vitro cytotoxicity than free PTX.
|
||||
| In Vitro Model | Glioblastoma | U-87MG cell | CVCL_0022 | ||
References